Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 8/20 | 0.37 |
| ▸ | THRA | P10827 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823472 | 0.92 | MEN1 (0.45) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10419884 | 0.89 | MEN1 (0.47) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10421420 | 0.88 | KMT2A (0.57) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL6479424 | 0.87 | MEN1 (0.59) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5560395 | 0.87 | MEN1 (0.43) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL7545405 | 0.86 | MEN1 (0.55) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10670462 | 0.85 | MEN1 (0.50) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10667155 | 0.85 | MEN1 (0.50) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10420835 | 0.84 | MEN1 (0.49) | MEN1NR1I2KMT2AP2RX7ABCB11 | |
| SCHEMBL10421482 | 0.84 | MEN1 (0.45) | MEN1NR1I2KMT2AP2RX7THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
| EP-1003729-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999002504-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0170316-B1 | ALPHA-ARYL-4-(4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZIN-2(3H)-YL)BENZENEACETONITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-30 | — | — | EP | disclosed |
| US-4778887-A | ANTIPROTOZOA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-18 | — | — | US | disclosed |
| US-4631278-A | Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-12-23 | — | — | US | disclosed |
| EP-0170316-A2 | alpha-Aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitriles | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042416-A1 | Antiinflammatory agents | CCR1, CCR6, FPR1 | MEN1 4743/4885NR1I2 384/4885KMT2A 4147/4885 |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | IL6, CCR1, CCR6 | MEN1 4804/4885NR1I2 624/4885KMT2A 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.